Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from preserved latanoprost to preservative‑free tafluprost in ocular hypertension or open‑angle glaucoma
2007-004872-37Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Oct 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tafluprost in ocular hypertension and open-angle glaucoma (OAG), sponsored by Santen Pharmaceutical. Primary endpoints: Changes in ocular signs, Changes in ocular symptoms and 1 more. Started Oct 2007; status: completed.
02
Drugs
tafluprost
03
Conditions
ocular hypertensionopen-angle glaucoma (OAG)
Beyond the preview
Go deeper on 2007-004872-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004872-37.